United Services Automobile Association Reduces Position in Emergent Biosolutions Inc (NYSE:EBS)

Share on StockTwits

United Services Automobile Association decreased its holdings in shares of Emergent Biosolutions Inc (NYSE:EBS) by 80.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,637 shares of the biopharmaceutical company’s stock after selling 67,302 shares during the quarter. United Services Automobile Association’s holdings in Emergent Biosolutions were worth $804,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Clarus Wealth Advisors grew its holdings in shares of Emergent Biosolutions by 30.7% during the second quarter. Clarus Wealth Advisors now owns 2,114 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 496 shares in the last quarter. KBC Group NV purchased a new stake in shares of Emergent Biosolutions during the second quarter worth $126,000. Marshall Wace North America L.P. grew its holdings in shares of Emergent Biosolutions by 250.5% during the first quarter. Marshall Wace North America L.P. now owns 4,700 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 3,359 shares in the last quarter. Connable Office Inc. purchased a new stake in shares of Emergent Biosolutions during the second quarter worth $262,000. Finally, Outlook Wealth Advisors LLC grew its holdings in shares of Emergent Biosolutions by 9.3% during the second quarter. Outlook Wealth Advisors LLC now owns 5,495 shares of the biopharmaceutical company’s stock worth $265,000 after buying an additional 468 shares in the last quarter. 87.81% of the stock is owned by institutional investors and hedge funds.

Shares of EBS opened at $52.58 on Friday. The company has a current ratio of 2.30, a quick ratio of 1.53 and a debt-to-equity ratio of 0.84. Emergent Biosolutions Inc has a 12-month low of $39.11 and a 12-month high of $73.89. The firm has a 50-day moving average price of $50.36 and a 200 day moving average price of $47.57. The firm has a market capitalization of $2.71 billion, a P/E ratio of 22.57, a P/E/G ratio of 0.86 and a beta of 1.54.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.16 by ($0.04). Emergent Biosolutions had a negative net margin of 2.04% and a positive return on equity of 6.68%. The firm had revenue of $243.20 million during the quarter, compared to analysts’ expectations of $217.94 million. During the same period in the prior year, the company posted $1.07 EPS. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. Equities research analysts predict that Emergent Biosolutions Inc will post 3.04 earnings per share for the current fiscal year.

In related news, Director Kathryn C. Zoon sold 1,509 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $56.12, for a total value of $84,685.08. Following the completion of the sale, the director now owns 21,494 shares of the company’s stock, valued at $1,206,243.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 14.10% of the company’s stock.

A number of research firms have recently issued reports on EBS. Guggenheim began coverage on shares of Emergent Biosolutions in a report on Thursday, September 12th. They set a “buy” rating and a $65.00 target price for the company. Laidlaw set a $72.00 target price on shares of Emergent Biosolutions and gave the stock a “buy” rating in a report on Wednesday, September 4th. Chardan Capital set a $71.00 target price on shares of Emergent Biosolutions and gave the stock a “buy” rating in a report on Tuesday, September 3rd. ValuEngine raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Wednesday, September 4th. Finally, Wells Fargo & Co raised shares of Emergent Biosolutions from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $61.00 to $64.00 in a report on Wednesday, September 4th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Emergent Biosolutions currently has a consensus rating of “Buy” and a consensus price target of $70.25.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Further Reading: What is the significance of the death cross?

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.